- Home
- ALGS vs DYAI Comparison
ALGS vs DYAI Comparison
Compare ALGS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | DYAI |
|---|---|---|
| Founded | 2018 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 32.5M |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ALGS | DYAI |
|---|---|---|
| Price | $5.69 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.33 | $3.00 |
| AVG Volume (30 Days) | 117.0K | ★ 248.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,186,000.00 | ★ $3,090,345.00 |
| Revenue This Year | $32.20 | $122.79 |
| Revenue Next Year | $4.71 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $0.65 |
| 52 Week High | $13.69 | $1.35 |
Technical Indicators
Market Signals| Indicator | ALGS | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 70.61 |
| Support Level | $4.80 | $0.76 |
| Resistance Level | $5.94 | $1.29 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 20.95 | 83.67 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.